; (ii) information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and period; and (iii) the rebate amount specified under such paragraph for such rebatable drug and period. (B) Manufacturer requirements The manufacturer of a rebatable drug, for such drug, shall meet each of the following requirements for each rebate period with respect to a calendar quarter beginning on or after July 1, 2019: (i) Rebate payment The manufacturer shall, not later than 30 days after the date of receipt of the information described in subparagraph (A) from the Secretary, provide to the Secretary a rebate that is equal to the amount specified in paragraph (4) for such drug for such rebate period. (ii) Report of ASP The manufacturer shall report to the Secretary the information described in section 1927(b)(3)(A)(iii) in a time and manner consistent with the reporting under such section, unless such information is already reported in accordance with section 1927(b)(3)(C). (3) Rebatable drug defined In this subsection, the term rebatable drug means a drug or biological (as defined in section 1847A(c)(6)(D)) paid for under this part, except such term shall not include such a drug or biological— (A) to the extent the units of such drug or biological are furnished as part of a grouping of items and services and paid for as such a grouping in an ambulatory payment classification under section 1833(t) or in a single payment under section 1833(i) (instead of separately payable under such respective section); (B) to the extent payment for the units of such drug or biological is included under the single payment system for renal dialysis services under section 1881(b)(14); (C) to the extent the average total allowed charges per year per individual that uses such drug or biological are less than $100